Coloplast (CPH:COLO B) Full Year 2024 Results
Key Financial Results
- Revenue: kr.27.0b (up 10% from FY 2023).
- Net income: kr.5.05b (up 5.6% from FY 2023).
- Profit margin: 19% (in line with FY 2023).
- EPS: kr.22.46 (up from kr.22.21 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Coloplast Meets Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations.
Looking ahead, revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 7.1% growth forecast for the Medical Equipment industry in Europe.
Performance of the market in Denmark.
The company's shares are down 1.6% from a week ago.
Risk Analysis
It is worth noting though that we have found 2 warning signs for Coloplast that you need to take into consideration.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About CPSE:COLO B
Coloplast
Engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally.
Fair value with moderate growth potential.
